Biogen is pricing Leqembi at $26,500 per year, and Medicare coverage is necessary for a drug that expensive to generate significant revenue and be available to a wide group of patients.

Health Biogen’s Alzheimer’s drug Leqembi has full FDA approval now. Here’s what that means. "This confirmatory study verified that it is a safe and effective treatment for patients with ...

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to ...

Biogen and Eisai are confident that the FDA will grant full approval for Leqembi for Alzheimer's disease. Find out why BIIB and ESALY could experience a substantial boost.

Leqembi, sold by partners Eisai Co Ltd , opens new tab and Biogen Inc , opens new tab at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's ...

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.

Biogen did not disclose how many patients are currently on Leqembi. The company in May said roughly 5,000 people were taking the drug. Still, Leqembi faces hurdles in Europe, where a drug ...

Eisai, Biogen's injectable Leqembi delayed as FDA asks for more data By Angus Liu Apr 1, 2024 10:45am Eisai Biogen Leqembi U.S. FDA ...

Leqembi’s $40 million in Q2 sales beat analyst expectations, as it had a slow uptake – bringing in just $10 million last year following its launch. Earlier this year, Biogen said about 5,000 people ...

Biogen and Eisai intend to increase their sales force by 30%, aiming for 100,000 patients by 2026. From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading it all ...

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.